Joseph Rocco Bertino (August 16, 1930 – October 11, 2021) was an American researcher in the cancer pharmacology program at Rutgers Cancer Institute of New Jersey and professor of medicine and pharmacology at the Robert Wood Johnson Medical School in New Jersey.
[1] After graduating from medical school at SUNY Downstate College of Medicine in 1954, Bertino did a USPHS fellowship in hematology and oncology at the University of Washington School of Medicine.
In 1958, he moved to Seattle to work with Clement A. Finch and Frank M.
[1] Following this, he was the chair of the Molecular Pharmacology and Therapeutics Program at Memorial Sloan-Kettering until 2002, when he moved to the Cancer Institute of New Jersey.
[3][4] Some of Bertino's notable scientific accomplishments are research into methotrexate and resistance to cancer treatments, including that use of methotrexate leads to an increase in dihydrofolate reductase.